Data as of Dec 04
| -0.01 / -0.52%|
Apricus Biosciences, Inc. is a pharmaceutical company, focused in the areas of oncology, sexual dysfunction, autoimmune and anti-infectives. Apricus also focusing primarily on research and development using its proprietary drug delivery technology called NexACT. Its pipeline of approved and late stage NexACT based product candidates includes Vitaros, Femprox, MycoVa, RayVa, PrevOnco and Nupen. The company operates its business through two segments: designing and developing pharmaceutical products with its NexACT drug delivery technology and providing pre-clinical contract research organization services. It has changed its name from NexMed, Inc. to Apricus Biosciences, Inc. in September 2010. The company was founded in 1987 and is headquartered in San Diego, CA.
|Richard W. Pascoe||Chief Executive Officer & Director|
|Steven Robert Martin||Chief Financial Officer & Senior Vice President|
|Linda Smibert||Vice President-Business Development|
|Mohamed Hachicha||Vice President-Research & Development|
|Edward M. Cox||VP-Investor Relations & Corporate Development|